<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552028</url>
  </required_header>
  <id_info>
    <org_study_id>GA19-00011</org_study_id>
    <nct_id>NCT04552028</nct_id>
  </id_info>
  <brief_title>Respiratory Dysfunction in Acute Pancreatitis (SAFI)</brief_title>
  <acronym>SAFI</acronym>
  <official_title>Correlation of Non-invasive and Invasive Oxygenation for the Diagnosis of Respiratory Dysfunction in Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Hector Eloy Tamez Perez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis (AP) is an inflammatory process of the pancreas and is one of the main&#xD;
      causes of hospital admission of gastrointestinal origin. The annual incidence is between 13&#xD;
      to 45 per 100,000 habitants. The etiology may correspond to vesicular gallstones, excessive&#xD;
      alcohol consumption, drugs, among others. Risk factors such as smoking and type 2 diabetes&#xD;
      mellitus have been found to increase the risk of pancreatitis by 1.86 to 2.89 times.&#xD;
&#xD;
      Pulmonary complications are the most frequent in this group of patients, approximately in 75%&#xD;
      of cases, they vary from hypoxemia to acute respiratory distress syndrome (ARDS). In the&#xD;
      first 2 days of hospital admission, tachypnea, mild respiratory alkalosis and hypoxemia may&#xD;
      occur, usually without radiological manifestations, however 33% of patients with AP have&#xD;
      pulmonary complications with symtoms and radiological signs, some of them are atelectasis&#xD;
      (15%), small pleural effusion (4-17%) mainly of right lung and pulmonary edema (8-50%).&#xD;
&#xD;
      Non-invasive methods would allow faster identification of patients with hypoxemia or patients&#xD;
      who have pulmonary organ failure. (6) There is no evidence on the usefulness of SpO2 / FiO2&#xD;
      (SF) as a predictor of hypoxemia and its correlation with PaO2 / FiO2 in acute pancreatitis,&#xD;
      however its continuous calculation can greatly reduce arterial gas intake and decrease&#xD;
      adverse events and costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basal period&#xD;
&#xD;
      Patients will be managed based on the most current acute pancreatitis clinical guidelines and&#xD;
      the requirements will be:&#xD;
&#xD;
        -  Complete medical history including: sex, age, history of chronic degenerative diseases,&#xD;
           pulmonary and/or cardiac diseases, alcohol consumption, onset of abdominal pain, body&#xD;
           mass index.&#xD;
&#xD;
        -  Laboratory tests: blood count, biochemical profile, amylase and serum lipase, complete&#xD;
           serum electrolytes, lipid profile, arterial blood gases.&#xD;
&#xD;
        -  Image studies:&#xD;
&#xD;
             -  Ultrasound of the upper abdomen to rule out biliary etiology&#xD;
&#xD;
             -  Computed tomography of simple abdomen in case of diagnostic doubt&#xD;
&#xD;
             -  Chest radiography&#xD;
&#xD;
        -  Pulse oximetry with Finger Pulse Oximeter Brand: Carejoy Model G11002&#xD;
&#xD;
        -  Severity of acute pancreatitis as follows:&#xD;
&#xD;
             -  Severity will be established based on the revised Atlanta 2012 Criteria.&#xD;
&#xD;
             -  The modified Marshall system will be evaluated to determine organic failure, which&#xD;
                is defined as: ≥ 2 points in any of the 3 organic systems evaluated (renal,&#xD;
                cardiovascular and pulmonary).&#xD;
&#xD;
             -  Variables will be obtained to determine systemic inflammatory response syndrome.&#xD;
&#xD;
      Intervention Arterial blood gases will be taken to calculate the PF ratio at admission and&#xD;
      every 24 hours, until the resolution of pancreatitis and/or the first 5 days of admission.&#xD;
&#xD;
      Pulse oximetry will be performed at the same time as arterial blood gases, to calculate the&#xD;
      SP ratio at admission and every 24 hours, until resolution of pancreatitis and/or the first 5&#xD;
      days of hospitalization.&#xD;
&#xD;
      Treatment The management of pancreatitis upon admission will be based on the established&#xD;
      clinical guidelines: Hartman IV solution at 20 mL/kg and subsequently infusion at 3 mL/kg/h&#xD;
      for the first 24 hours.&#xD;
&#xD;
      Follow up&#xD;
&#xD;
      According to the state of severity of acute pancreatitis, the following groups will be&#xD;
      formed:&#xD;
&#xD;
        -  Mild: Without multiple organic failure or ARDS&#xD;
&#xD;
        -  Moderately severe or ARDS &lt;48 hours&#xD;
&#xD;
        -  Severe or ARDS&gt; 48 hours&#xD;
&#xD;
      To assess respiratory dysfunction, 2 groups will be formed:&#xD;
&#xD;
        -  No respiratory dysfunction: PF&gt; 300&#xD;
&#xD;
        -  Respiratory dysfunction: PF &lt;300&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Days</target_duration>
  <primary_outcome>
    <measure>To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.</measure>
    <time_frame>5 days</time_frame>
    <description>Pulse oximetry will be performed at the same time as arterial blood gases, to calculate the SP ratio at admission and every 24 hours, until resolution of pancreatitis and/or the first 5 days of hospitalization.</description>
  </primary_outcome>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Complication</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non invasive oxygenation</intervention_name>
    <description>To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to &quot;Dr. José Eleuterio González&quot; University Hospital from November 2019,&#xD;
        with diagnosis of acute pancreatitis of any etiology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with acute pancreatitis with clinical, radiological or laboratory&#xD;
             criteria.&#xD;
&#xD;
          -  All genders&#xD;
&#xD;
          -  Acute pancreatitis of any aetiology&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lung diseases&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Cholangitis&#xD;
&#xD;
          -  Acute cholecystitis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Refuse to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolanda P Toalque Aldana, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Univesitario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tolaque Aldana</last_name>
    <phone>+528132322204</phone>
    <email>pattytolaque@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel O Jaquez Quintana, M.D.</last_name>
    <phone>+528114183484</phone>
    <email>jomjaqui@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario José Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda P Tolaque Aldana, M.D.</last_name>
      <phone>+528132322204</phone>
      <email>pattytolaque@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dr. med. Hector Eloy Tamez Perez</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

